亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial

医学 表阿霉素 危险系数 内科学 临床终点 多西紫杉醇 乳腺癌 肿瘤科 吉西他滨 环磷酰胺 外科 化疗 随机对照试验 癌症 置信区间
作者
Min He,Yizhou Jiang,Yue Gong,Lei Fan,Xiyu Liu,Yin Liu,Li-Chen Tang,Miao Mo,Yifeng Hou,Gen‐Hong Di,Guang‐Yu Liu,Ke‐Da Yu,Jiong Wu,Yan Xia,Xiaohua Zeng,Deyuan Fu,Chuangui Song,Zhigang Zhuang,Kejin Wu,Jie Wang
出处
期刊: [BMJ]
卷期号:387: e079603-e079603 被引量:20
标识
DOI:10.1136/bmj-2024-079603
摘要

Abstract Objective To evaluate the feasibility of using a multigene signature to tailor individualised adjuvant therapy for patients with operable triple negative breast cancer. Design Randomised, multicentre, open label, phase 3 trial. Setting 7 cancer centres in China between 3 January 2016 and 17 July 2023. Participants Female patients aged 18-70 years with early triple negative breast cancer after definitive surgery. Interventions After risk stratification using the integrated signature, patients at high risk were randomised (1:1) to receive an intensive adjuvant treatment comprising four cycles of docetaxel, epirubicin, and cyclophosphamide followed by four cycles of gemcitabine and cisplatin (arm A; n=166) or a standard treatment of four cycles of epirubicin and cyclophosphamide followed by four cycles of docetaxel (arm B; n=170). Patients at low risk received the same adjuvant chemotherapy as arm B (arm C; n=168). Main outcome measures The primary endpoint was disease-free survival in the intention-to-treat analysis for arm A versus arm B. Secondary endpoints included disease-free survival for arm C versus arm B, recurrence-free survival, overall survival, and safety. Results Among the 504 enrolled patients, 498 received study treatment. At a median follow-up of 45.1 months, the three year disease-free survival rate was 90.9% for patients in arm A and 80.6% for patients in arm B (hazard ratio 0.51, 95% confidence interval (CI) 0.28 to 0.95; P=0.03). The three year recurrence-free survival rate was 92.6% in arm A and 83.2% in arm B (hazard ratio 0.50, 95% CI 0.25 to 0.98; P=0.04). The three year overall survival rate was 98.2% in arm A and 91.3% in arm B (hazard ratio 0.58, 95% CI 0.22 to 1.54; P=0.27). The rates of disease-free survival (three year disease-free survival 90.1% v 80.6%; hazard ratio 0.57, 95% CI 0.33 to 0.98; P=0.04), recurrence-free survival (three year recurrence-free survival 94.5% v 83.2%; 0.42, 0.22 to 0.81; P=0.007), and overall survival (three year overall survival 100% v 91.3%; 0.14, 0.03 to 0.61; P=0.002) were significantly higher in patients in arm C than in those in arm B with the same chemotherapy regimen. The incidence of grade 3-4 treatment related adverse events were 64% (105/163), 51% (86/169), and 54% (90/166) for arms A, B, and C, respectively. No treatment related deaths occurred. Conclusions The multigene signature showed potential for tailoring adjuvant chemotherapy for patients with operable triple negative breast cancer. Intensive regimens incorporating gemcitabine and cisplatin into anthracycline/taxane based therapy significantly improved disease-free survival with manageable toxicity. Trial registration ClinicalTrials.gov NCT02641847 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
朴实香氛完成签到,获得积分10
4秒前
13秒前
jackieshark发布了新的文献求助10
18秒前
无奈的绾绾完成签到,获得积分10
22秒前
45秒前
cc发布了新的文献求助10
51秒前
忧伤的傲芙完成签到,获得积分10
55秒前
1分钟前
CipherSage的应助被cc采纳,获得30
1分钟前
高兴之柔完成签到,获得积分10
1分钟前
希望天下0贩的0的应助被SUNny采纳,获得10
1分钟前
彪壮的从阳完成签到,获得积分10
1分钟前
Criminology34的应助被科研通管家采纳,获得10
1分钟前
Criminology34的应助被科研通管家采纳,获得10
1分钟前
英俊的铭的应助被科研通管家采纳,获得10
1分钟前
虚幻的雁山完成签到,获得积分10
1分钟前
2分钟前
勤劳的翩跹完成签到,获得积分10
2分钟前
不安鱼完成签到 ,获得积分20
2分钟前
科研通AI6.4的应助被雪山大地采纳,获得10
2分钟前
jianjian发布了新的文献求助30
2分钟前
笨笨妙彤完成签到,获得积分10
3分钟前
大方的钥匙完成签到,获得积分10
3分钟前
fantasy的应助被科研通管家采纳,获得10
3分钟前
Criminology34的应助被科研通管家采纳,获得20
3分钟前
在水一方的应助被科研通管家采纳,获得30
3分钟前
3分钟前
领导范儿的应助被科研通管家采纳,获得10
3分钟前
Criminology34的应助被科研通管家采纳,获得10
3分钟前
null的应助被科研通管家采纳,获得10
3分钟前
谦让的忆枫完成签到,获得积分10
4分钟前
4分钟前
4分钟前
NeoAir完成签到 ,获得积分10
4分钟前
独特珩完成签到,获得积分10
4分钟前
hamburger完成签到,获得积分10
4分钟前
4分钟前
雪山大地发布了新的文献求助10
4分钟前
含蓄的雪冥完成签到,获得积分10
5分钟前
雪山大地发布了新的文献求助10
5分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166228
求助须知:如何正确求助?哪些是违规求助? 9559445
关于积分的说明 21750389
捐赠科研通 7757027
什么是DOI,文献DOI怎么找? 3429137
关于科研通互助平台的介绍 2553436
邀请新用户注册赠送积分活动 2473781